Andreessen Horowitz and investors including GV, Two Sigma Ventures, Third Rock Ventures, Foresite Capital Management, Arch Venture Partners, Wuxi AppTec, HOF Capital, Casdin Capital, BlackRock, T. Rowe Price Group, and Canada Pension Plan Investment Board, participated in the $143m Series B round for insitro, a machine-learning driven drug discovery and development company. "With this financing, as well as milestones we have achieved through our strategic partnership with Gilead, we are in a strong position to continue executing on our vision,” Daphne Koller, insitro Founder and CEO.